ArticleBiomaterials research2026
Restoring Zinc Homeostasis via a Bimetallic Nanozyme to Amplify Ferroptosis and Antitumor Immunity for Prostate Cancer Treatment.
Article in Biomaterials research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Prostate cancer therapy is hindered by treatment resistance and an immunosuppressive microenvironment. To address this, we developed an innovative bimetallic nanozyme, Fe/Zn-CNZ@LOx@PEG, that integrates catalytic activity with metabolic and immune modulation. This nanoplatform executes a novel "metabolic-immuno" co-regulation strategy. Its Fe-Zn catalytic sites drive a lactate-fueled cascade reaction within the acidic tumor milieu, generating a burst of cytotoxic hydroxyl radicals. Simultaneously, released zinc ions rectify tumor zinc deficiency, disrupting cellular metabolism and promoting ferroptosis-an iron-dependent cell death-through glutathione depletion and lipid peroxidation. This ferroptotic cell death, in turn, acts as a potent trigger for immunogenic cell death (ICD), stimulating dendritic cell maturation and cytotoxic T cell infiltration to reverse immunosuppression. Consequently, Fe/Zn-CNZ@LOx@PEG demonstrates potent tumor suppression and effectively enhances the efficacy of anti-PD-1 therapy in a prostate cancer mouse model. This work presents a catalytic nanoreactor that co-regulates metabolism and immunity, offering a robust and synergistic strategy for the ferroptosis-immunotherapy of advanced cancers.
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.